Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.

Emma G SturgillAmanda MischCarissa C JonesDaniel LuckettXiaotong FuDan SchlauchSuzanne F JonesHoward A BurrisDavid R SpigelAndrew J McKenzie

Published in: The oncologist (2022)

This study uncovers variability in bTMB reporting among commercial NGS platforms, thereby evidencing a need for assay-specific thresholds in identifying patients who may respond to CPI therapy.

Keyphrases

high throughput
risk factors
emergency department
stem cells
bone marrow
cell therapy
replacement therapy